Adults with type 1 diabetes achieved improved glycemic and patient-reported outcomes with the DBLG1 hybrid closed-loop system. Findings were presented at the European Association for the Study of Diabetes Conference 2025.

This prospective cohort study enrolled 167 adults across 12 specialized centers in Belgium. Participants used the DBLG1 system integrated with an insulin pump and continuous glucose monitoring sensor. Clinical and CGM data were collected at baseline, 4, 8, and 12 months.

Time in range (3.9–10.0 mmol/L) increased from 57% at baseline to 69% at 12 months (p<0.001). The proportion of patients achieving the consensus target of >70% TIR rose from 18% to 47%. HbA1c decreased from 7.6% to 7.0% (p<0.001). Time spent in hypoglycemia (<3.9 mmol/L) fell from 3.7% to 1.4% (p<0.001). Patient-reported outcomes improved significantly, including lower Hypoglycemia Fear Survey-II scores, reduced diabetes-related distress, and higher treatment satisfaction. Self-reported severe hypoglycemic events dropped from 28.5 to 1.7 events per 100 person-years.

The study demonstrated that 12 months of DBLG1 system use improved glycemic control, minimized hypoglycemia, and enhanced quality of life in adults with type 1 diabetes.